CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Mar 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-03-20

Reporting Person: Elsbernd Brian (Chief Compliance/Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-20	Common Stock, par value $0.001 per share	M	50000	$1.13	Acquired	188076	Direct
2023-03-20	Common Stock, par value $0.001 per share	S	50000	$16.069	Disposed	138076	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-20	Options to Purchase Common Stock	$1.13	M	50000	Disposed	2024-01-03	Common Stock (50000)	Direct

Footnotes

F1: Mr. Elsbernd sold the shares in the open market for personal reasons and not as a result of a disagreement with the Company. Mr. Elsbernd remains an executive officer of the Company.

F2: Represents the weighted average price for the shares sold. Shares were sold in various lots ranging from $16.01 to $16.23 per share.

F3: Options vested in three annual tranches beginning on 1/3/2018.